Funduscopic appearance of anti-VEGF- treatment naïve patient with 20/32 baseline vision and Diabetic Macular Edema
Funduscopic appearance of anti-VEGF- treatment naïve patient with 20/32 baseline vision and Diabetic Macular Edema

For a patient with Diabetic Macular Edema (DME), the overarching goal is to preserve vision. Early detection, monitoring, and timely referral is important.1-3

DME is a complication of Diabetic Retinopathy (DR) that can occur at any time.4 A severity scale can help identify and standardize the clinical features of DR at various stages and allow for early detection and timely intervention.1,5-7

Learn More

CI-DME and Worsening Vision, 20/32 Baseline Vision



54 years of age


Onset 18 months

No previous anti-VEGF treatment

Clinical Findings

Previous Visit

ETDRS-DRSS: Moderately severe NPDR (level 47)

ETDRS Letters: 75

Snellen Equivalent: 20/32

CRT: 596 μm

HbA1c: 7.9

Current Visit

ETDRS-DRSS: Severe NPDR (level 53)

ETDRS Letters: 70

Snellen Equivalent: 20/40

CRT: 627 μm

HbA1c: 7.9

Medical History

Comorbidities: Type 2 diabetes (6 years), hypercholesterolemia, NPDR, cataracts, cataract extraction with intraocular lens implant, posterior vitreous detachment

Familial: Mother had type 2 diabetes with vision loss

Note: This is a representative case example that you may encounter in clinical practice.

anti-VEGF = anti–vascular endothelial growth factor; CI-DME = central-involved DME; CRT = central retinal thickness; ETDRS-DRSS = Early Treatment Diabetic Retinopathy Study–Diabetic Retinopathy Severity Scale; HbA1c = glycated hemoglobin; NPDR = nonproliferative diabetic retinopathy; OD = right eye.


Commercial (Avastin-first policy)

Timely Refer Appropriate Patients to a Retina Specialist Who Can Treat DME2,3

See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information and Indications INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.


  1. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;98(5 suppl):823-833.
  2. Care of the Patient With Diabetes Mellitus: Quick Reference Guide. American Optometric Association website. http://bit.ly/2M22OUJ. Accessed January 14, 2020.
  3. Ferrucci S, Yeh B. Diabetic retinopathy by the numbers. Rev Optom. June 15, 2016. http://bit.ly/2KNNJ4E. Accessed January 14, 2020.
  4. Macular Edema. National Eye Institute, National Institutes of Health website. http://bit.ly/2MGKMVG. Accessed January 14, 2020.
  5. Davis MD, Fisher MR, Gangnon RE, et al; for the Early Treatment Diabetic Retinopathy Study Research Group. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18. Invest Ophthalmol Vis Sci. 1998;39(2):233-252.
  6. Staurenghi G, Feltgen N, Arnold JJ, et al. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies. Br J Ophthalmol. 2018;102(7):954-958.
  7. American Academy of Ophthalmology. Preferred Practice Pattern®: Diabetic Retinopathy. http://bit.ly/2SX3H2D. Accessed January 14, 2020.